CAR T therapies drive into new terrain

Nature Reviews Drug Discovery 16, 301 (2017). doi:10.1038/nrd.2017.84 Author: Katie Kingwell The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research